Biomagnetics Diagnostics Corp. has accepted delivery of a novel biosensor developed at Los Alamos National Laboratory. The sensor, which is proposed for use in cholera, tuberculosis and malaria diagnosis, could be in clinical trials by 2012. Biomagnetics Diagnostics Corp. is set to further develop and commercialize a novel integrated optical biosensor developed at Los Alamos National Laboratory. (Image: Business Wire) The biosensor uses planar waveguides to bring protein-receptor pairs into proximity with one another, thus triggering detectable fluorescence. It was created by Biomagnetics Diagnostics through a cooperative research and development agreement with Los Alamos National Security LLC. “An integrated optical biosensor device holds the promise to allow relatively untrained medical personnel to diagnose a variety of diseases in a matter of only a few minutes,” said Clayton Hardman, the company’s CEO. “We will be proceeding with our plans to re-engineer the technology into a format that can be utilized for clinical trials and commercialization later this year.” For more information, visit: www.biomagneticsbmgp.com